1. Home
  2. BLLN vs MMS Comparison

BLLN vs MMS Comparison

Compare BLLN & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BLLN

BillionToOne Inc.

N/A

Current Price

$83.95

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo Maximus Inc.

MMS

Maximus Inc.

HOLD

Current Price

$59.43

Market Cap

3.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
MMS
Founded
2016
1975
Country
United States
United States
Employees
713
N/A
Industry
Medical Specialities
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.6B
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
BLLN
MMS
Price
$83.95
$59.43
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$126.71
N/A
AVG Volume (30 Days)
575.7K
718.9K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
2.02%
EPS Growth
N/A
10.42
EPS
N/A
3.50
Revenue
N/A
$2,392,236,000.00
Revenue This Year
$46.29
$0.44
Revenue Next Year
$30.14
$5.15
P/E Ratio
N/A
$17.18
Revenue Growth
N/A
N/A
52 Week Low
$61.96
$57.32
52 Week High
$138.70
$100.00

Technical Indicators

Market Signals
Indicator
BLLN
MMS
Relative Strength Index (RSI) 49.23 29.64
Support Level $79.33 N/A
Resistance Level $97.36 $70.49
Average True Range (ATR) 8.45 2.56
MACD 0.37 -0.53
Stochastic Oscillator 35.65 13.15

Price Performance

Historical Comparison
BLLN
MMS

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Share on Social Networks: